Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
You may also be interested in...
Off The WHO Hook, Sanofi CEO Viehbacher Plans To Take Shantha's Vaccines To The World
HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches
Off The WHO Hook, Sanofi CEO Viehbacher Plans To Take Shantha's Vaccines To The World
HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.